873052-13-2

Basic information

• Product Name: 4-oxo-N'-(4-fluorophenyl)-1,4-dihydroquinoline-3-carboxamide
• CAS NO: 873052-13-2
• Molecular Weight: 282.274
• Mol File: 873052-13-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-oxo-N'-(4-fluorophenyl)-1,4-dihydroquinoline-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-oxo-N'-(4-fluorophenyl)-1,4-dihydroquinoline-3-carboxamide(873052-13-2)
• EPA Substance Registry System: 4-oxo-N'-(4-fluorophenyl)-1,4-dihydroquinoline-3-carboxamide(873052-13-2)

Safety Data

• Hazardous Substances Data: 873052-13-2(Hazardous Substances Data)

Upstream product

• 87-51-4 indole-3-acetic acid 
• 54535-22-7 diethyl (anilinomethylene)malonate 
• 62-53-3 aniline 
• 52980-28-6 ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 371-40-4 4-fluoroaniline 

Relevant articles and documents

PROCESS FOR THE SYNTHESIS OF IVACAFTOR AND RELATED COMPOUNDS

The present patent discloses a novel one pot two-step process for the synthesis of ivacaftor and related compounds of [Formula (I)], wherein R1, R2, R3, R4, R5, R6, R7 and Ar1 are as described above; its tautomers or pharmaceutically acceptable salts thereof starting from indole acetic acid amides.

Synthesis, cytotoxicity and mechanistic evaluation of 4-oxoquinoline-3- carboxamide derivatives: Finding new potential anticancer drugs

As part of a continuing search for new potential anticancer candidates, we describe the synthesis, cytotoxicity and mechanistic evaluation of a series of 4-oxoquinoline-3-carboxamide derivatives as novel anticancer agents. The inhibitory activity of compounds 10-18 was determined against three cancer cell lines using the MTT colorimetric assay. The screening revealed that derivatives 16b and 17b exhibited significant cytotoxic activity against the gastric cancer cell line but was not active against a normal cell line, in contrast to doxorubicin, a standard chemotherapeutic drug in clinical use. Interestingly, no hemolytical activity was observed when the toxicity of 16b and 17b was tested against blood cells. The in silico and in vitro mechanistic evaluation indicated the potential of 16b as a lead for the development of novel anticancer agents against gastric cancer cells.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.